The trajectory of companies tied to flagship drugs like Viagra presents a challenging investment landscape . While the initial rise of copyright, fueled by Viagra's extraordinary popularity, generated substantial returns, the loss of exclusivity in key territories has introduced substantial volatility. Investors are now facing the consequences of r